Carrier screening by next-generation sequencing: Health benefits and cost effectiveness

Molecular Genetics and Genomic Medicine

Volumn 4, Issue 3, 2016, Pages 292-302

  Azimi, Mohammad ^a   Schmaus, Kyle ^a   Greger, Valerie ^b   Neitzel, Dana ^b   Rochelle, Robert ^b   Dinh, Tuan ^a  

^a EVIDERA   (United States)

^b Good Start Genetics Inc   (United States)

Author keywords

Carrier screening; Cost effectiveness; Genotyping; Next generation sequencing

Indexed keywords

EID: 84990022105     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.204     Document Type: Article

References (41)

1. American Congress of Obstetricians and Gynecologists. 2009. ACOG Committee Opinion No. 442: preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet. Gynecol. 114:950-953.
2. American Congress of Obstetricians and Gynecologists. 2011. ACOG Committee Opinion No. 486: update on carrier screening for cystic fibrosis. Obstet. Gynecol. 117:1028-1031.
3. Amos, J., G. L. Feldman, W. W. Grody, K. Monaghan, G. E. Palomaki, and T. Prior. 2006. American College of Medical Genetics: technical standards and guidelines for CFTR mutation testing: 2006 Edition [Online]. American College of Medical Genetics, Bethesda, MD. Available at https://www.acmg.net/Pages/ACMG_Activities/stds-2002/cf.htm (accessed 20 June 2014).
4. Arias, E. 2014. United States life tables, 2009. National Center for Health Statistics, Hyattsville, MD. Available at http://www.cdc.gov/nchs/data/nvsr/nvsr62/nvsr62_07.pdf. Natl. Vital Stat. Rep. 62:1-63.
5. Bell, C. J., D. L. Dinwiddie, N. A. Miller, S. L. Hateley, E. E. Ganusova, J. Mudge, et al. 2011. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci. Transl. Med. 3:65ra64.
6. Benn, P., H. Cuckle, and E. Pergament. 2013. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet. Gynecol. 42:15-33.
7. Ben-Yosef, T., S. L. Ness, A. C. Madeo, A. Bar-Lev, J. H. Wolfman, Z. M. Ahmed, et al. 2003. A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome. N. Engl. J. Med. 348:1664-1670.
8. Briggs, A. H., M. C. Weinstein, E. A. Fenwick, J. Karnon, M. J. Sculpher, and A. D. Paltiel. 2012. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med. Decis. Making 32:722-732.
9. Brock, D. J. 1996. Prenatal screening for cystic fibrosis: 5 years’ experience reviewed. Lancet 347:148-150.
10. Caro, J., D. M. Eddy, H. Kan, C. Kaltz, B. Patel, R. Eldessouki, et al. 2014. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 17:174-182.
11. Chou, J. Y., D. Matern, B. C. Mansfield, and Y. T. Chen. 2002. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr. Mol. Med. 2:121-143.
12. Counsyl, 2010. The universal genetic test-disease book v1.0.55. Counsyl, Inc., Redwood City, CA.
13. Davie, J., N. Faulkner, and V. Greger. 2015. Carrier screening of 48,761 patients in the IVF setting utilizing next generation DNA sequencing detects common, rare and otherwise undetectable pathogenic variants in prevalent, society-recommended diseases. Abstract P-18. Presented at the 63rd Annual Meeting of the Pacific Coast Reproductive Society, March 11-15, 2015. Fertil. Steril. 103(2 Suppl):e17.
14. Edelmann, L., J. Dong, R. J. Desnick, and R. Kornreich. 2002. Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population. Am. J. Hum. Genet. 70:1023-1027.
15. Ekstein, J., B. Y. Rubin, S. L. Anderson, D. A. Weinstein, G. Bach, D. Abeliovich, et al. 2004. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am. J. Med. Genet. A 129A:162-164.
16. Garfield, S. S., and S. O. Armstrong. 2012. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J. Managed Care Med. 15:34-41.
17. Grody, W. W., B. H. Thompson, A. R. Gregg, L. H. Bean, K. G. Monaghan, A. Schneider, et al. 2013. ACMG position statement on prenatal/preconception expanded carrier screening. Genet. Med. 15:482-483.
18. Gross, S. J., B. A. Pletcher, K. G. Monaghan, and Professional Practice Guidelines Committee. 2008. Carrier screening in individuals of Ashkenazi Jewish descent. Genet. Med. 10:54-56.
19. Hallam, S., H. Nelson, V. Greger, C. Perreault-Micale, J. Davie, N. Faulkner, et al. 2014. Validation for clinical use of, and initial clinical experience with, a novel approach to population-based carrier screening using high-throughput, next-generation DNA sequencing. J. Mol. Diagn. 16:180-189.
20. Heim, R. A., E. A. Sugarman, and B. A. Allitto. 2001. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel. Genet. Med. 3:168-176.
21. Kaback, M. M. & R. J. Desnick. 1999. [Updated 2011]. Hexosaminidase A deficiency. in: Pagon, R. A., Adam, M. P., Ardinger, H. H., et al. eds. Gene reviews [Internet]. University of Washington, Seattle, WA. Available at http://www.ncbi.nlm.nih.gov/books/NBK1218/ (accessed 5 January 2015)
22. Ki, C. S., S. H. Han, H. J. Kim, S. G. Lee, E. J. Kim, J. W. Kim, et al. 2004. Mutation spectrum of the glucose-6-phosphatase gene and its implication in molecular diagnosis of Korean patients with glycogen storage disease type Ia. Clin. Genet. 65:487-489.
23. Kronn, D., V. Jansen, and H. Ostrer. 1998. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY. Arch. Intern. Med. 158:777-781.
24. Kumar, P., J. Radhakrishnan, M. A. Chowdhary, and P. F. Giampietro. 2001. Prevalence and patterns of presentation of genetic disorders in a pediatric emergency department. Mayo Clin. Proc. 76:777-783.
25. Lebo, R. V., and V. S. Tonk. 2015. Analyzing the most frequent disease loci in targeted patient categories optimizes disease gene identification and test accuracy worldwide. J. Transl. Med. 13:16.
26. Ness, S. L., T. Ben-Yosef, A. Bar-Lev, A. C. Madeo, C. C. Brewer, K. B. Avraham, et al. 2003. Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III. J. Med. Genet. 40:767-772.
27. Nestorowicz, A., B. A. Wilson, K. P. Schoor, H. Inoue, B. Glaser, H. Landau, et al. 1996. Mutations in the sulfonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum. Mol. Genet. 5:1813-1822.
28. Park, N. J., C. Morgan, R. Sharma, Y. Li, R. M. Lobo, J. B. Redman, et al. 2010. Improving accuracy of Tay Sachs carrier screening of the non-Jewish population: analysis of 34 carriers and six late-onset patients with HEXA enzyme and DNA sequence analysis. Pediatr. Res. 67:217-220.
29. Perreault-Micale, C., A. Frieden, C. J. Kennedy, D. Neitzel, J. Sullivan, N. Faulkner, et al. 2014. Truncating variants in the majority of the cytoplasmic domain of PCDH15 are unlikely to cause Usher syndrome 1F. J. Mol. Diagn. 16:673-678.
30. Perreault-Micale, C., J. Davie, B. Breton, S. Hallam, and V. Greger. 2015. A rigorous approach for selection of optimal variant sets for carrier screening with demonstration of clinical utility. Mol. Genet. Genomic Med. 3:363-373.
31. Radhakrishnan, M., K. van Gool, J. Hall, M. Delatycki, and J. Massie. 2008. Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 85:133-147.
32. Richards, C. S., L. A. Bradley, J. Amos, B. Allitto, W. W. Grody, A. Maddalena, et al. 2002. Standards and guidelines for CFTR mutation testing. Genet. Med. 4:379-391.
33. Rowley, P. T., S. Loader, and R. M. Kaplan. 1998. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am. J. Hum. Genet. 63:1160-1174.
34. Scotet, V., M. de Braekeleer, M. Roussey, G. Rault, P. Parent, M. Dagorne, et al. 2000. Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years’ experience and impact on prenatal diagnosis. Lancet 356:789-794.
35. Scotet, V., M. P. Audrezet, M. Roussey, G. Rault, M. Blayau, M. de Braekeleer, et al. 2003. Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France. Hum. Genet. 113:280-285.
36. Scott, S. A., L. Edelmann, L. Liu, M. Luo, R. J. Desnick, and R. Kornreich. 2010. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum. Mutat. 31:1240-1250.
37. Snowdon, C., and J. M. Green. 1997. Preimplantation diagnosis and other reproductive options: attitudes of male and female carriers of recessive disorders. Hum. Reprod. 12:341-350.
38. Song, K., T. J. Musci, and A. B. Caughey. 2013. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J. Matern. Fetal Neonatal Med. 26:1180-1185.
39. Umbarger, M. A., C. J. Kennedy, P. Saunders, B. Breton, N. Chennagiri, J. Emhoff, et al. 2014. Next-generation carrier screening. Genet. Med. 16:132-140.
40. Victor Center. 2015. Victor Center for the Prevention of Jewish Genetic Diseases [Online]. Victor Center, Philadelphia, PA. Available at http://www.victorcenters.org/(accessed 5 January 2015)
41. Watson, M. S., G. R. Cutting, R. J. Desnick, D. A. Driscoll, K. Klinger, M. Mennuti, et al. 2004. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet. Med. 6:387-391.